$2.34 Billion is the total value of Camber Capital Management LP's 26 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | Buy | SPDR S&P 500 ETF TRput | $581,440,000 | +114.3% | 2,000,000 | +100.0% | 24.88% | +138.4% |
| MYL | Buy | MYLAN N V | $137,250,000 | +51.9% | 3,750,000 | +50.0% | 5.87% | +69.0% |
| TSRO | Buy | TESARO INC | $136,535,000 | +22.8% | 3,500,000 | +40.0% | 5.84% | +36.6% |
| MCK | New | MCKESSON CORP | $99,488,000 | – | 750,000 | +100.0% | 4.26% | – |
| PRGO | Buy | PERRIGO CO PLC | $70,800,000 | +5.0% | 1,000,000 | +8.1% | 3.03% | +16.8% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $51,398,000 | +13.0% | 1,750,000 | +75.0% | 2.20% | +25.7% |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $34,388,000 | – | 750,000 | +100.0% | 1.47% | – |
| ZYME | Buy | ZYMEWORKS INC | $21,556,000 | +16.7% | 1,373,000 | +9.8% | 0.92% | +29.7% |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $20,217,000 | +2.3% | 291,600 | +11.7% | 0.86% | +13.8% |
| STRO | New | SUTRO BIOPHARMA INC | $9,000,000 | – | 600,000 | +100.0% | 0.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.